Day 2Tuesday, 24 March 2026

NeuroSoV is a privately held, pre-clinical-stage biopharmaceutical company headquartered in Portugal. The company pioneers the development of disease-modifying therapies for neurodegenerative disorders, with a primary focus on Parkinson’s Disease (PD).

Leveraging deep knowledge of oxidative-stress-driven mechanisms and NADPH oxidase (NOX) biology, NeuroSoV is advancing a first-in-class, brain-penetrant ionic-liquid-based inhibitor of NOXs – a key source of reactive oxygen species implicated in PD pathogenesis. This patented technology represents a differentiated therapeutic approach designed to slow disease progression, protect dopaminergic neurons, and preserve motor function, thereby improving patients’ quality of life and independence.

With over €3 million raised through national and EU competitive programs (PT2030, FCT, Horizon Europe, WomenTechEU), and strong intellectual-property protection in major markets, NeuroSoV is actively seeking strategic partnerships and co-development opportunities to advance its lead candidate toward IND/CTA readiness and first-in-human evaluation. By uniting multidisciplinary science, innovation, and entrepreneurship, NeuroSoV aims to change the natural course of Parkinson’s Disease and redefine therapeutic intervention in neurodegeneration.

Lario Therapeutics Limited is a preclinical-stage drug discovery company based in Edinburgh (UK). Lario has been incubated and co-founded by Epidarex-Exeed and Axxam SpA (now Golgi Neurosciences) and is developing first-in-class precision medicines for epileptic and neurological disorders. Lario’s pipeline is composed of genetically validated programs with a key focus on the development of novel therapies for severe pediatric syndromes including CACNA1E (DEE69) and CDKL5 (DEE2). Both of these severe genetic disorders are characterised by treatment-resistant forms of epilepsy, profound developmental delay and movement difficulties. In addition to the disease-modifying focus on rare pediatric genetic syndromes, Lario’s projects also target various drug-refractory forms of epilepsy as well as other neurological disorders including Parkinson’s disease, PTSD and familiar hemiplegic migraine. Lario is rapidly advancing and currently in partnering discussions with various pharma and VC firms. In addition, Lario recently received significant funding from the Michale J. Fox Foundation (MJFF) and the Wellcome Trust.

Tonix is a biotechnology company where scientific breakthroughs begin with respecting the patient’s lived experience. Our pipeline responds to the call for solutions to complex, chronic and sometimes invisible conditions with scientific rigor, integrity, and purpose. We are dedicated to developing therapies for conditions that defy easy answers, including nociplastic pain, immunology / immuno-oncology, and infectious diseases. We aim to develop impactful treatments that make patients feel seen and heard, reducing the limitations these conditions impose, enabling people to expect more, and be energized by possibility. At Tonix, we listen, we develop, we deliver – so that patients feel seen, heard, and empowered to live fully again.

Curlim is a late pre-clinical biotech developing an innovative encapsulation platform designed to improve the therapeutic efficacy of bioactive molecules. Founded in 2024 as a spin-off from the University of Limoges, Curlim brings together three PhD scientists and a C-level Business person to tackle one of the biggest unmet needs in neurology: effective treatment for hereditary peripheral neuropathies and neurodegenerative diseases. Our operational team is composed of an over 20 year experience CDO, bringing his expertise to all our workflows, CMC, preclinical and clinical studies, a PhD in neuroscience in charge of regulatory affairs and preclinical aspects, a development engineer involved in the development of CLM001 nanodrug, a FP&A junior manager dealing with administrative and finance topics and a CEO who has held C-level positions across various healthcare environments. Our first mission: to develop a breakthrough therapy for Charcot-Marie-Tooth disease type 1A (CMT1A) — the most common hereditary neuropathy, caused by progressive demyelination and axonal damage.

Neurizon Therapeutics is a clinical-stage biotechnology company developing disease-modifying therapies that target the underlying pathology of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), Huntington’s disease, and Frontotemporal Dementia. Our lead program, NUZ-001, is a first-in-class oral therapy designed to address core mechanisms of neurodegeneration, including TDP-43 protein aggregation and impaired autophagy. Because TDP-43 pathology is present in more than 95% of ALS cases and is implicated across multiple neurodegenerative conditions, NUZ-001 has the potential to serve as a scalable, multi-indication platform therapy. NUZ-001 has completed Phase 1 and Open-Label Extension studies, demonstrating a favourable safety and tolerability profile with encouraging signals across key clinical measures—significantly de-risking its advancement. The program is being included in the Phase 2/3 HEALEY ALS Platform Trial Regimen I, an established, registration-level framework offering an accelerated and highly capital-efficient path to potential approval.

Ophidion has a brain-centric Trojan horse technology that is capable of delivering gene-silencing cargoes (such as siRNAs or ASOs), proteins and peptides to the brain following intravenous administration (as opposed to more invasive technologies focusing on intra-thecal or intra-cranial delivery). This intravenous delivery approach ensures uniform distribution to all regions of the brain at a fraction of the dose used by competitors delivered intrathecally. As a matter of fact, Ophidion’s dose used in its lead program to treat Huntington’s disease is 1/1,000 times that used by Roche intrathecally in their preclinical models. Up to 3.5% of the intravenously injected dose remains in the brain three weeks following an IV dose.

Ophidion has established preclinical proof of concept in the most severe humanized Huntington's mice where a complete halting of disease progression was established (stopped the disease more than 95%) in two chronic studies. In addition, Ophidion successfully completed repeat dose ranging studies in non-human primates (monkeys), where a significant protein knock-down was observed in the Huntington’s protein in various brain regions implicated in Huntington’s disease following intravenous administration of the lead oligonucleotide, complexed to our Trojan horse, a demonstration that our technology works in larger animal species. Ophidion technology can be used to treat other neurodegenerative diseases with gain in function, such as ALS, Alzheimer’s disease, Parkinson’s disease, Fronto-Temporal Dementia, etc. In addition, we have succeeded in delivering large proteins to the brain following IV administration to treat brain cancer and Alzheimer’s disease.

With this preclinical proof of concept data in hand, we are currently looking to raise our Series A financing, targeting $25M. With this financing, we plan to advance multiple assets targeting various neurodegenerative diseases.

Evox Therapeutics is an Oxford-based biotechnology company dedicated to developing transformative therapeutics for neurological and neurodegenerative diseases by uniting engineered exosomes with next-generation genome editors.

Evox is advancing a focused pipeline of first-in-class therapeutics for genetically defined CNS disorders. Our lead ATXN2 programme for spinocerebellar ataxia type 2 and amyotrophic lateral sclerosis is on track for CTA-enabling studies set to begin in 2026. A second programme targeting MSH3 for Huntington’s disease is progressing in parallel, and the modular nature of ExoEdit™ positions us to scale rapidly across additional repeat-expansion and other genetically defined indications.

Evox’s growth is funded by blue-chip investors, including Redmile, OrbiMed, GV, Invus, and Lilly, and reinforced by validating strategic partnerships.

Avata Biosciences is a privately owned clinical stage pharmaceutical company with a lead asset, AVAT-021, in clinical studies.

Avata's patented technology platform is able to generate both solid-dose and water-soluble synthetic cannabinoid formulations suitable for targeting CNS diseases with high unmet needs in both adults and children.

The lead asset AVAT-021 will be developed in adult focal-onset seizures (FOS), using the 505(b)(2) regulatory pathway with Epidiolex® as the reference product. A single Phase 3 study to commence in 2027.

In addition to the FOS program, Avata has entered into a partnership with Oxford University to assess AVAT-021 in Schizophrenia with a Phase 2 study starting 2026.

Avata Biosciences is keen to explore strategic partnering opportunities with pharmaceutical companies.

SeaBeLife is a French biotechnology company developing first-in-class small molecules to prevent irreversible tissue damage and organ failure by inhibiting regulated cell death pathways, including necroptosis and ferroptosis. SeaBeLife’s proprietary platform has generated a robust pipeline of ~150 patented compounds, supported by a strong multi-family IP position with issued patents in major territories. SeaBeLife is advancing two lead programs addressing major unmet medical needs in large markets: SBL01, an intravenous solution targeting life-threatening acute and orphan liver injuries/failures (ALI/ALF/ACLF), and SBL03, a non-invasive ophthalmic formulation designed to preserve vision in Dry Age-related Macular Degeneration (Dry-AMD / Geographic Atrophy) by directly targeting retinal cell death mechanisms. SeaBeLife has demonstrated compelling in vivo proof-of-concept for both programs. EMA Orphan Drug Designation has been granted for SBL01, and IND-enabling activities are underway for the both programs with FiH expected to start early 2027. SeaBeLife’s approach is highly differentiated, including dual inhibition of necroptosis and ferroptosis in liver indications and a unique non-invasive ophthalmic strategy targeting key cell death mechanisms involved in geographic atrophy. SeaBeLife is actively seeking strategic partnering opportunities with pharmaceutical companies and investors to accelerate clinical development and maximize patient impact, including out-licensing, co-development, R&D collaborations, and potential M&A discussions, at key value-inflection points.

Rejuvenate Biomed is a clinical-stage & platform company developing oral safe combination therapeutics to treat age-related diseases. Our lead compound RJx-01is geared toward sarcopenia (muscle health) and has shown in humans an excellent safety and tolerability, clinical efficacy (muscle strength, function and fatigue resistance) and a transformative mechanism of action (boosted mitochondrial energy, reduced inflammation, reversed fibrosis). Clinical Phase 2b data inflection points for disease-induced sarcopenia and treatment-induced sarcopenia are end 2026 and mid 2027 respectively.

Evogene Ltd. (Nasdaq/TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries.

At the core of its technology is ChemPass AI, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs.

Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products driven by the integration of scientific innovation with real-world industry needs. We call this approach “Real-World Innovation“.

Metatissue is a biotechnology company dedicated to developing human protein-derived biomaterials that bring in vitro models significantly closer to human physiology. By replacing animal-derived matrices with scalable, xeno-free solutions, Metatissue enables researchers and developers to generate more reliable, predictive, and reproducible data for drug discovery, toxicity testing, disease modelling, and regenerative medicine.

Our proprietary platforms, hPLMA and hPCMA, are engineered from ethically sourced human proteins, from blood and placenta, and designed to emulate essential features of the human extracellular matrix. These biomaterials offer tunable biochemical and mechanical properties that support physiologically relevant cell behavior, enhance cell-to-matrix interactions, and improve the fidelity of 3D culture systems. Through their human-specific composition, our materials help reduce translational gaps and increase the success rate of preclinical research.

Metatissue can serve a broad range of customers, including biopharma and biotech companies developing advanced therapeutics, CROs and CDMOs integrating human-relevant matrices into testing pipelines, and academic or clinical research groups working in stem cell biology, oncology, immunology, and tissue engineering. Our technologies are also compatible with organ-on-chip devices, bioprinting, and emerging platforms for personalized medicine.

Founded by scientists with deep expertise in tissue engineering and biomaterials, Metatissue is committed to transforming how human biology is studied in vitro. By advancing human-derived matrices that deliver higher physiological relevance, we empower researchers and companies to reduce animal dependency, improve preclinical predictiveness, and accelerate scientific discovery across multiple therapeutic areas.

NanoSyrinx is an award-winning, discovery stage biotechnology company based in the UK. We are using synthetic biology approaches to develop protein Nanosyringes as a completely novel modality for targeted, intracellular delivery of protein and peptide biologic drugs.

Our vision at NanoSyrinx is to unlock the interior of the cell and the myriad therapeutic opportunities within that are currently difficult (or impossible) to drug, by enabling targeted, intracellular delivery of protein therapeutics. See www.nanosyrinx.com/video

NanoSyrinx closed a £10m financing round in August 2024, led by BGF (London), M Ventures (Amsterdam) and Octopus Ventures (London) and supported by Eli Lilly and Company, IQ Capital (Cambridge) and Jonathan Milner (Cambridge).

Divamics Inc. is an AI-driven drug discovery company that integrates molecular dynamics with physics-based force fields to accelerate innovation. We are dedicated to pioneering R&D to create innovative medicines that address unmet medical needs, supported by two core platforms: the Molecular Dynamics Platform and the BioTrajectory Database Platform, designed to help researchers identify novel leads and PCCs with higher efficiency.

Alphabiome is pioneering a data-driven approach to decoding the microbiome and predicting drug response through an advanced AI-genomics engine. Founded by MIT AI experts and backed by a Scientific Advisory Board including Stanford Nobel Laureates in chemistry and genetics, the company has built a proprietary platform that decodes the unmapped 99.9% of microbial DNA. The technology has been validated through the world's largest animal microbiome trial (30,000 dairy cows) and has demonstrated successful human proof-of-concept by doubling treatment efficacy for Crohn’s and Colitis in clinical cohorts. By identifying over 100,000 novel biomarkers, Alphabiome delivers proprietary, IP-protected insights that turn biological complexity into commercial-grade assets.

MindLab is a U.S.-based biotech company developing MLB-001, a next-generation, morphine-class pain therapeutic designed to deliver morphine-level efficacy with a more controlled clinical profile. Our initial focus is acute pain and severe acute pain, where patients need rapid, reliable relief and clinicians need options that balance efficacy with responsible use.

MLB-001 is designed to provide strong analgesia with dose-sparing potential and a longer, more consistent therapeutic window, while aiming to reduce reward-driven drug liking that can contribute to misuse and diversion. MindLab’s development strategy emphasizes regulator-ready clinical execution, including first-in-human safety/PK studies and dedicated human abuse-liability assessment, to support differentiated positioning for patients, providers, and health systems.

MindLab is seeking strategic partners and investors to accelerate clinical development, regulatory progression in the U.S. and Europe, and future commercialization—particularly collaborators with expertise in pain, clinical operations, and market access.

ISOBiotech is a rapidly emerging Australian start-up revolutionising the field of molecular diagnostics. Backed by nearly two decades of expertise, we have developed a proprietary isothermal amplification technology - Isothermal PCR Amplification (IPA™) - that delivers rapid, accurate, and scalable detection of any known infectious disease.

At the core of our innovation is IPA™, a novel amplification chemistry that pairs seamlessly with our compact, portable, easy-to-use diagnostic platform, the RapidDetector™. Together, they enable fast, reliable, and decentralised testing, without the need for complex instrumentation or laboratory infrastructure.

ISOBiotech’s In Vitro Diagnostic (IVD) intended solutions, certified to ISO13485:2016 standards, can transform the way infectious diseases, cancers or genetic disorders are detected, monitored and managed, by empowering clinicians and public health systems with tools that are accurate, affordable, and accessible. Our technology is well-suited to meet global demands for point-of-care diagnostics, especially in resource-limited settings or during health emergencies such as epidemics and pandemics.

HyQure BioTech Co., Ltd. (HYQURE) is a technology-driven, one-stop biosafety CRO specializing in viral safety and quality control for biologics and cell & gene therapy products. We support programs from discovery through commercialization with GLP/GMP-aligned viral clearance and inactivation studies, cell bank characterization, raw material testing, replication-competent virus assays (RCL, rcAAV, RCR, RCA), AAV and viral vector characterization, process residue testing (HCP/residual DNA), and commercial lot release testing. HYQURE operates CNAS-accredited BSL-2 laboratories in China and has expanded its global network with a European site in Basel, Switzerland. We have supported 300+ biopharmaceutical clients and 100+ regulatory submissions, including FDA/EMA/TGA-approved cases, providing regulatory-ready data packages to reduce CMC risk, avoid delays, and accelerate IND/BLA milestones.

LimmaTech Biologics is at the forefront of combating the global antimicrobial resistance epidemic based on its unparalleled track record in vaccine technology and clinical candidate development. The company is leveraging its proprietary self-adjuvanting and multi-antigen vaccine platform alongside additional disease-specific vaccine approaches to prevent increasingly untreatable microbial infections. With decades of expertise and an expanding, robust company pipeline, the LimmaTech team is dedicated to generating protective solutions to deliver transformative value worldwide.

Shaperon is a clinical-stage biotechnology company headquartered in Seoul, South Korea, focused on the development of innovative therapies for immune and inflammatory diseases with high unmet medical need. Leveraging deep expertise in immunology and inflammatory signaling, Shaperon builds differentiated programs spanning both small molecules and next-generation biologics.

Shaperon’s core pipeline is built around novel small-molecule GPCR19 positive allosteric modulators (PAMs). Unlike prior GPCR19 approaches that failed due to mixed orthosteric-allosteric binding profiles and suboptimal selectivity, Shaperon’s compounds selectively engage a distinct allosteric site, avoiding GPCR19 orthosteric related safety issues such as gallbladder filling and cardiotoxicity. This enables precise modulation of the GPCR19 receptor signaling pathway, resulting in broad suppression of inflammatory cytokine release by controlling both the priming and activation phases of inflammasome. This dual-phase regulation differentiates Shaperon's approach from other conventional inflammasome-targeting therapies that focus only on the activation phase. Shaperon has applied this strategy across multiple clinical programs advancing in inflammatory indications, including atopic dermatitis, diabetic foot ulcers, Alzheimer's disease, and idiopathic pulmonary fibrosis.

In parallel, Shaperon has established a proprietary nanobody platform, NanoMab, based on alpaca-derived single-domain antibodies. Integrated with high-throughput screening and rapid optimization workflows, the NanoMab platform enables the generation of highly stable nanobodies within approximately three months. The platform supports multi-specific formats, offering modularity and flexible target engagement. NanoMabs serve as a foundation for Shaperon’s expansion into novel oncology and antiviral biologics, addressing complex diseases beyond the reach of conventional antibodies.

Alphyn is developing a pipeline of Multi-Target Therapeutics® for dermatology based on its unique Zabalafin Drug Platform. The Platform is an impactful innovation because it has multiple bioactive compounds with multiple mechanisms of action to treat individual diseases in multiple ways, be more efficacious, and and treat multiple diseases. Importantly, drugs from our platform have strong safety, side effect, and patient tolerability profiles.

The company’s lead candidate, Zabalafin Hyrdogel (ZH), is completing Phase 2b trials to address the $41B opportunity in atopic dermatitis (AD). Results are expected Q2-2026. Based on Phase 2a results and interim blinded results, Alphyn believes ZH is uniquely positioned to be the first drug to directly target AD’s four key and interconnected problems – itch, inflammation, bacteria, and dry skin.

Alphyn’s second drug indication for ZH treats molluscum contagiosum virus (MCV), uniquely directly targeting the disease’s multiple problems that include for the first time directly killing the virus itself, itch, inflammation and, in certain patients, dermatitis and bacterial infection with its associated pain. It is currently nearing close of enrollment in the Phase 2 clinical trial with results expected early Q3-2026.

Alphyn has a strong patent portfolio, with U.S. patent protection to 2043, and a notice of allowance from the European patent office expected to publish in the Q1-2026. Global applications for additional patents are underway. Alphyn’s market protection is enhanced with the addition of health authority compliant drug raw material supply sufficient to provide $4.8 Billion in sales.

Alphyn closed a $25 million, twice over-subscribed Series B financing in 2025, bringing the company’s total raised to more than $33 million since it became operational in 2020.